CN102631482B - Chinese medicinal composition for preventing and treating diabetes and complications - Google Patents
Chinese medicinal composition for preventing and treating diabetes and complications Download PDFInfo
- Publication number
- CN102631482B CN102631482B CN201210146660.1A CN201210146660A CN102631482B CN 102631482 B CN102631482 B CN 102631482B CN 201210146660 A CN201210146660 A CN 201210146660A CN 102631482 B CN102631482 B CN 102631482B
- Authority
- CN
- China
- Prior art keywords
- extract
- diabetes
- folium mori
- vitis viniferae
- fructus arctii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 239000000284 extract Substances 0.000 claims abstract description 86
- 239000003814 drug Substances 0.000 claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 8
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 39
- 235000009392 Vitis Nutrition 0.000 claims description 35
- 241000219095 Vitis Species 0.000 claims description 35
- 210000000582 semen Anatomy 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 48
- 230000036541 health Effects 0.000 abstract description 6
- 239000008187 granular material Substances 0.000 abstract description 5
- 244000269722 Thea sinensis Species 0.000 abstract description 4
- 240000005373 Panax quinquefolius Species 0.000 abstract description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 3
- 240000005528 Arctium lappa Species 0.000 abstract description 2
- 235000003130 Arctium lappa Nutrition 0.000 abstract description 2
- 244000146462 Centella asiatica Species 0.000 abstract description 2
- 235000004032 Centella asiatica Nutrition 0.000 abstract description 2
- 240000000249 Morus alba Species 0.000 abstract description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 abstract description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 abstract description 2
- 240000006365 Vitis vinifera Species 0.000 abstract description 2
- 235000014787 Vitis vinifera Nutrition 0.000 abstract description 2
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 239000007902 hard capsule Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000006187 pill Substances 0.000 abstract 1
- 239000007901 soft capsule Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 58
- 210000004369 blood Anatomy 0.000 description 52
- 239000008280 blood Substances 0.000 description 52
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 29
- 102000004877 Insulin Human genes 0.000 description 29
- 108090001061 Insulin Proteins 0.000 description 29
- 229960001031 glucose Drugs 0.000 description 29
- 239000008103 glucose Substances 0.000 description 29
- 229940125396 insulin Drugs 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 22
- 201000001421 hyperglycemia Diseases 0.000 description 22
- 239000000047 product Substances 0.000 description 18
- 230000006870 function Effects 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000002218 hypoglycaemic effect Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 230000035922 thirst Effects 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 229920002414 procyanidin Polymers 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 5
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 5
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 5
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 5
- 230000023852 carbohydrate metabolic process Effects 0.000 description 5
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 229960005139 epinephrine Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229960001052 streptozocin Drugs 0.000 description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000033679 diabetic kidney disease Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000016912 Aldehyde Reductase Human genes 0.000 description 3
- 108010053754 Aldehyde reductase Proteins 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- YZNNBIPIQWYLDM-HSUXUTPPSA-N Fagomine Chemical compound OC[C@H]1NCC[C@@H](O)[C@@H]1O YZNNBIPIQWYLDM-HSUXUTPPSA-N 0.000 description 3
- YZNNBIPIQWYLDM-ZLUOBGJFSA-N Fagomine Natural products OC[C@@H]1NCC[C@H](O)[C@H]1O YZNNBIPIQWYLDM-ZLUOBGJFSA-N 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- YZNNBIPIQWYLDM-UHFFFAOYSA-N L-fagomine Natural products OCC1NCCC(O)C1O YZNNBIPIQWYLDM-UHFFFAOYSA-N 0.000 description 3
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 239000010977 jade Substances 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 2
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 2
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010007749 Cataract diabetic Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 108010001394 Disaccharidases Proteins 0.000 description 2
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 2
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 102100040200 Mitochondrial uncoupling protein 2 Human genes 0.000 description 2
- 101710112393 Mitochondrial uncoupling protein 2 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 2
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 2
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 2
- 229940011658 asiatic acid Drugs 0.000 description 2
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960000673 dextrose monohydrate Drugs 0.000 description 2
- 201000007025 diabetic cataract Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- -1 drying Substances 0.000 description 2
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 2
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 2
- 229940011656 madecassic acid Drugs 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 208000022530 polyphagia Diseases 0.000 description 2
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- NKYAAYKKNSYIIW-XVFCMESISA-N 5-aminoimidazole ribonucleoside Chemical compound NC1=CN=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NKYAAYKKNSYIIW-XVFCMESISA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- RFAWQHFQFXXRQB-UHFFFAOYSA-N Arctigenin 4'-gentiobioside Natural products CC1OC(OC2C(O)C(O)C(CO)OC2OC3C(O)C(O)C(OC4CCC5(C)C(CCC6(C)C5CC=C7C8CC(C)(C)CC(O)C8(C)CCC67C)C4(C)CO)OC3C(=O)O)C(O)C(O)C1O RFAWQHFQFXXRQB-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 206010066786 Diabetic keratopathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 239000009022 Jinqi Substances 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- FEQSYBHDHIPRKS-UHFFFAOYSA-N N5-Ac-(??)-N5-Hydroxyornithine Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(CO)O4)O)O3)O)=CC=2)C(=O)OC1 FEQSYBHDHIPRKS-UHFFFAOYSA-N 0.000 description 1
- ATKYNAZQGVYHIB-IXXDHKBRSA-N Norhyoscyamine Natural products C1([C@@H](C(=O)OC2C[C@H]3CC[C@H](N3)C2)CO)=CC=CC=C1 ATKYNAZQGVYHIB-IXXDHKBRSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- ATKYNAZQGVYHIB-IZGVIRRGSA-N [(1r,5s)-8-azabicyclo[3.2.1]octan-3-yl] (2s)-3-hydroxy-2-phenylpropanoate Chemical compound C1([C@H](C(=O)OC2C[C@H]3CC[C@H](N3)C2)CO)=CC=CC=C1 ATKYNAZQGVYHIB-IZGVIRRGSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- ATKYNAZQGVYHIB-UHFFFAOYSA-N tropaic acid nortropanyl ester Natural products C1C(N2)CCC2CC1OC(=O)C(CO)C1=CC=CC=C1 ATKYNAZQGVYHIB-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a Chinese medicinal composition for preventing and treating related diseases such as diabetes and complications thereof. The Chinese medicinal composition comprises American ginseng or extract thereof, mulberry leaves or extract thereof, centella asiatica or extract thereof, great burdock achene or extract thereof, and grape seeds or extract thereof. Oral preparations such as hard capsules, soft capsules, tablets, granules, powder, pills, tea bags, medicinal liquor and oral liquid are prepared from the five combinations by utilizing the synergistic effects of each component. The composition can be applied to Chinese patent medicaments or health care products, and has the effect of preventing and treating the related diseases such as the diabetes and the complications thereof.
Description
Technical field
The invention belongs to medicine and field of food, is the compositions that a kind of natural product with relevant diseases such as the diabetes of preventing and treating and complication thereof is made.
Background technology
Diabetes are that by insulin definitely or relative deficiency and the chronic endocrine metabolism disease that causes its main feature is hyperglycemia and multiple complications and deposits.The sickness rate of China's diabetes presents increases trend year by year, and wherein 90% is non-insulin-dependent diabetes mellitus.The patient adds up to 4,000 ten thousand, predicts China's diabetics in 2025 according to WHO and will break through 5,000 ten thousand.The diabetes characteristics are that chronic hyperglycemia is followed because of insulin secretion and acts on sugar, fat and the protein metabolism disorder that defect causes.Its long-term hyperglycemia, hyperlipidemia are the major reasons that causes the body visceral organ injury, therefore, correct the important means that the glycolipid metabolism disorder is treatment diabetes and complication thereof.The infringement of rule of life, diet, environment, emotion and all kinds of chemical substances that it and people are daily has close relationship.Its basic pathology physiology is the absolute or relative hyposecretion of insulin in body, thereby causes carbohydrate, fat, protein, the metabolism disorder of power and water solution matter.Diabetes (hyperglycemia) all can exert an influence to each age group, have become the public health problem in serious threat human health and life-span.
People think that diabetes are that insulin function goes down or insulin function is impaired and cause more, and hypoinsulinism in the diabetics body, cause blood sugar increasing.In fact, most type 2 diabetes mellitus patients' islet function does not have large infringement, and function is within normal range, and wherein 80% patient also has hyperinsulinemia.Therefore, be not insulin very little, but due to insulin resistant, normal biological effect deficiency, cause blood glucose high, and too high blood glucose is only the direct inducement of many complication.The reason that produces insulin resistant mainly contains the insulin molecule structure defectiveness of B cell secretion, does not have normal physiological function, the Insulin receptor INSR deficiency, and in conjunction with reducing, histiocyte is to insulin insensitivity; The impact of insulin antibody and make insulin lose due function of blood sugar reduction; The hormonal readiness of antagonism insulin increases, to hypoglycemic activity of glucagon etc., therefore reduce or eliminate insulin resistant, normocrinic insulin in body is played one's part to the full, just can reach and reduce blood sugar level and fundamentally eliminate diabetes and complication.
At present, the oral drugs for prevention and treatment diabetes (hyperglycemia) on domestic and international market are a lot, and Chinese medicine is arranged, and Western medicine is also arranged.Western medicine mainly contains sulfonylurea as glyburide, minidiab, and biguanides is as metformin, metformin, and glucosidase inhibitor is as acarbose etc.Chinese medicine mainly contains JIANGTANGSHU, JINQI JIANGTANG PIAN, YUQUAN WAN, jade plate Xiaoke Tablets etc.These medicines, in treatment and prevent diabetes, are removed on diabetes patient's misery and have been played great role.But, along with the variation with disease that increases of diabetes patient's quantity, develop the medicine or the health product that prevent safer and more effectively and treat diabetes (hyperglycemia) and remain a very significant job.
The present invention is exactly a kind of Chinese medicine composition with relevant diseases such as the diabetes of preventing and treating and complication thereof of finding and extract from natural plants.Said composition is to become composition of natural products by the effective ingredient innovative combination, from several different mechanism of action treatment diabetes of starting with, reaches combination of long drives and drop shots, and the effect for the treatment of both the principal and secondary aspects of a disease, to having significant breakthrough and raising from efficacy and saferry.
The root that Radix Panacis Quinquefolii is Araliaceae Radix Panacis Quinquefolii Panax quinquefolium L..Also name Radix Panacis Quinquefolii " property of medicine is examined ", Radix Panacis Quinquefolii " middle traditional Chinese medicines are planted will " etc.Sweet in the mouth, micro-hardship, cool in nature.GUIXIN, lung, kidney channel.Function with lung benefiting the moon, clear asthenic fire, promoting the production of body fluid to quench thirst.Cure mainly deficiency of the lung chronic cough, lose blood, dry throat and mouth, deficiency-heat be tired tired.The ginseng polysaccharide that Radix Panacis Quinquefolii contains hypoglycemic activity, called after karusanA, B, C, D, E and water solublity crude pectin, hydrochloric acid soluble pectin, aminoacid, trace element and saponin.The results of study such as John Zeqi Luo show, Radix Panacis Quinquefolii has the effect that the balance the body glucose reaches dynamic equilibrium, the cause of disease of most of glycosuria diseases be due to the function of pancreatic beta cell excreting insulin destroyed due to.The preliminary study discovery, Radix Panacis Quinquefolii extract can suppress the activity of the UCP-2 in the pancreatic beta cell mitochondrion, improves insulin synthesis ability and anti-apoptotic.So, Radix Panacis Quinquefolii extract can stimulate by the activity that suppresses mitochondrion UCP-2 the generation of insulin, the loss of prevention β cell, result causes the raising of ATP level, the increase of cloning Bcl-2, lower short apoptosis factor caspase-9 simultaneously, thereby reduce apoptotic generation.In the research to effective ingredient Rb1, the Rg of Radix Panacis Quinquefolii such as HasegawaH, find, the ginsenoside has the function that promotes suction pressure under normal conditions, the ginsenoside Rb1 just can increase the suction pressure physiologically active of (24 ± 5%) under the concentration conditions of minimum 1mmol/L, and the ginsenoside Rg3 also shows the important function that suppresses sheep red blood cell (SRBC) running glucose to inducing.The people such as Yokozawa T study discovery, and the ginsenoside Rb2 can activate lipid metabolism and the carbohydrate metabolism of rat model.So illustrate, Radix Panacis Quinquefolii can reduce blood glucose, regulates insulin secretion, promote carbohydrate metabolism and lipid metabolism, the treatment diabetes are had to certain assosting effect.
The dried leaves that Folium Mori are moraceae plants Mulberry Morus alba L..There is dispelling wind and heat pathogens, clearing away lung-heat and moistening for dryness, the effect of liver heat removing and eyesight improving, mainly contain flavone, polysaccharide and alkaloid.Compendium of Material Medica record Folium Mori are hands, the bright medicine of foot sun, control the consumptive fever cough, and the improving eyesight long hair, only quench one's thirst.Japan's ancient book " eating tea health preserving note " is also put down in writing the effect that Folium Mori are improved " drinking-water is sick ".Essentials of Matea Medica record Folium Mori are only quenched one's thirst for tea.The studying data at home and abroad confirmation, alkaloid and polysaccharide are blood sugar reducing components main in Folium Mori.The hypoglycemic activity of Folium Mori is realized by two approach: the one, and by the alkaloid 1-DNJ, disaccharides catabolic enzyme activity is produced to inhibitory action, thereby suppress the absorption of small intestinal to disaccharidase, reduce the peak value (Kimura, 1995) of the rear blood glucose of food; The 2nd, promoting by Folium Mori alkaloid fagomine and polysaccharides of Folium Mori that the β cell divides must insulin, and insulin can promote cell to sugared utilization, hepatic glycogen is synthetic and improve carbohydrate metabolism, finally reaches hypoglycemic effect (Chen Fujun etc., 1996).From Folium Mori, isolated polyhydroxy norhyoscyamine has very strong glycosidase inhibiting function (Asano etc., 1994); N-Me-DNJ, GAL-DNJ and fagomine can reduce blood sugar level significantly, wherein GAL-DNJ and fagomine hypoglycemic activity the strongest (Kimura etc., 1995).The rat diabetes that Folium Mori cause alloxan at ecdysterone; Or the mice hyperglycemia that epinephrine, glucagon, AIS cause all has hypoglycemic activity.Ecdysterone promotes that glucose changes glycogen into, but does not change intact animal's blood sugar level.Someone thinks that contained some aminoacid can stimulate the secretion of insulin to reduce blood glucose in Folium Mori.Simultaneously, Folium Mori are edible resource, there is no toxic and side effects, and the safety using amount of 1 lumbar injection of 10% Folium Mori injection mice is equivalent to 250 times of people's consumption.To be equivalent to 60 times of people's consumption continuously to mouse peritoneal injection 21 days, harmless to liver, kidney, lung etc.
Herba Centellae is the herb of samphire Herba Centellae Centella asiatica Linn., begins to be stated from Shennong's Herbal, classifies middle product as, and bitter, acrid, cold, return the liver,spleen,kidney warp, has clearing away heat-damp and promoting diuresis, the effect of removing toxic substances and promoting subsidence of swelling.For jaundice due to damp-heat, heatstroke diarrhoea, sand Stranguria stranguria with blood, carbuncle sore tumefacting virus, traumatic injury.Research in recent years report Herba Centellae has the promotion wound healing, softening cicatrix, and psoriasis, antidepressant, resisting hyperplasia of mammary glands, anti-hepatic fibrosis, anticancer, the treatment edema, protect the liver the effects such as treatment of blood sugar lowering and complication.The effective ingredient of Herba Centellae is asiatic centella total saponins, asiatic acid, Madecassic acid etc., Song Chun studies clearly and has reported that effective ingredient asiatic acid, the Madecassic acid in the Herba Centellae has the effect that reduces post-prandial glycemia and prevent and treat diabetes, and its principle is that the activity by Inhibiting α-glucosidase produces effect; Zheng Chenghong studies discovery, the Herba Centellae aqueous extract has obvious reduction blood sugar level, lose weight, reduce blood fat and insulin resistance index level, improve the effect of type 2 diabetes mellitus Insulin Resistance of Rats, it reduces effect and the metformin therapeutic equivalence of blood glucose, blood lipid level, and its effect that reduces the IRI level is better than metformin.Wang Xuesong research finds, Asiatic polysaccharide have protein phosphatase PTP1B inhibitor effect, and regulate immune effect.
The dry mature fruit that Fructus Arctii is Compositae biennial herb plant Fructus Arctii Arctium lappa L..Cold in nature, acrid in the mouth, hardship.Dispelling wind and heat pathogens, lung qi dispersing rash, resolving toxin and disinhibiting the throat.For anemopyretic cold, cough with copious phlegm, measles, rubella, laryngopharynx swelling and pain, mumps erysipelas, carbuncle sore tumefacting virus.Fructus Arctii is containing Arctiin (arctiin), arctigenin-4'-gentiobioside A, B, fatty wet goods composition.Fructus Arctii has inhibitory action to staphylococcus aureus, Diplococcus pneumoniae.Extract can reduce rat blood sugar significantly enduringly.Chinese medicine institute of Shanghai Univ. of Traditional Chinese Medicine studies confirm that, Fructus Arctii treatment diabetic nephropathy (DN) mechanism and reduction urine protein, microdose urine protein and to affect nephridial tissue transforming growth factor p1 (TGF-p1) relevant with the expression of monokaryon chemotactic protein 1 (MCP-1) mRNA.It is animal model that research worker be take the diabetes rat that streptozotocin (STZ) induces, result shows, Fructus Arctii extract can obviously improve STZ rat polydipsia, polyphagia and become thin, and reduces urine protein, microdose urine protein, reduces the expression of TGF-p1mRNA, MCP-1mRNA.The renal damage that improves diabetes rat may be expressed by alleviating MCP-1mRNA by Fructus Arctii extract.Fructus Arctii and extract thereof can effectively reduce the diabetes rat microdose urine protein, reach twenty-four-hour urine albumen, endogenous creatinine clearance rate.Fructus Arctii and extract thereof can reduce the blood sugar level of DN rat, reduce the excretion rate of urine protein, can filter by the height that alleviates the DN rat kidney, HT, thus renal function protecting.Bibliographical information Fructus Arctii extract has stronger aldose reductase inhibitory action, can for the preparation of the control diabetic complication---as the medicine of diabetic cataract, retinopathy, keratopathy and diabetic peripheral neuropathy.
Semen Vitis viniferae is the leftover bits and pieces of grape wine factory, separates products therefrom after Pericarpium Vitis viniferae, stem of Fructus Vitis viniferae after drying.Semen Vitis viniferae contains abundant aminoacid, vitamin, mineral and a large amount of procyanidins.Grape Seed Extract Procyanidin (OPC) is a kind of efficient free radical scavenger.The oxidative function of its free radical resisting is 50 times, ascorbic 20 times of vitamin E.Can remove poisonous free radical in human body, the protection human cell tissue exempts from, by the oxidative damage of free radical, to prevent the diseases relevant with free radical of kind more than 80 such as allergy, cancer, aging.Just be based on this effect of Semen Vitis viniferae, European people claims that Semen Vitis viniferae is cosmetics in natural body, and it can recover the collagen protein vigor, makes skin level and smooth and flexible.Semen Vitis viniferae or natural sunlight overcover, can stop ultraviolet infringement skin.Semen Vitis viniferae can reduce low density cholesterol in blood, can improve the level of HDL-C simultaneously, and both take into account, thus angiocardiopathy preventing.In addition, Semen Vitis viniferae extract contains abundant vitamin E, and vitamin E is famous antioxidant, so the effect of Semen Vitis viniferae also comprises the prevention various diseases, makes skin and the muscle state of keeping fit simultaneously.Semen Vitis viniferae also has anti-prostate tumor and anti-liver neoplasm effect.Thereby the protection Human autopsy tissues, prevent and treat more than 100 kind of heart disease, cancer, senilism, diabetes, arteriosclerosis etc. by the caused disease of free radical.
In sum, five kinds of Chinese medicine share with different effective substances has very clear and definite blood sugar lowering pharmacology effect from different action target spots and approach, can be by diabetes patient's blood glucose regulation to normal level.Therefore said composition can be used for medicine and the health product that preparation has the relevant diseases such as the diabetes of preventing and treating and complication thereof.
Summary of the invention
The inventor rest on a scientific basis theory, through repetition test, what selected the Ministry of Public Health regulation is that food and medicine and the medicine that can be used for health food carry out prescription, so this prescription forms very safe, without any side effects.Choose the Radix Panacis Quinquefolii that can directly take, Folium Mori, Fructus Arctii, Herba Centellae, five kinds of raw materials of Semen Vitis viniferae and there is the health food for the treatment of diabetes and complication thereof in order to prepare the present invention.When each raw material of choosing health food of the present invention carries out combination collocation, must consider the effect that they can be brought into play separately and the trade-off effect that they are arranged in pairs or groups and can produce.At first, select Radix Panacis Quinquefolii, because Radix Panacis Quinquefolii is by changing the metabolism of cell, increase the secretion of insulin, the apoptosis that reduces cell works to beta Cell of islet, promotes carbohydrate metabolism and lipid metabolism, blood fat reducing simultaneously and platelet aggregation rate, can obviously improve diabetic symptom, as weak, xerostomia etc.Theory of Chinese medical science is also thought Radix Panacis Quinquefolii sweet in the mouth, micro-hardship, cold in nature, and applicable crowd is extensive.There is supplementing QI and nourishing YIN, promoting the production of body fluid to quench thirst, allaying tiredness, the Fructus Alpiniae Oxyphyllae of calming the nerves, the effect of cool heart spleen to fall asthenic fire and to relieve summer heat.Selecting Folium Mori, is because Folium Mori have the reduction blood fat, suppresses the effect of the generation of harmful peroxide, contain 1-DNJ (DNJ) in Folium Mori, DNJ is as the inhibitor of alpha-glucosidase, thereby the inhibition small intestinal reduces the peak value of the rear blood glucose of food to the absorption of disaccharidase; Polysaccharides of Folium Mori promotes β emiocytosis insulin, and insulin can promote cell synthesize and improve carbohydrate metabolism sugared utilization, hepatic glycogen, finally reaches hypoglycemic effect.Theory of Chinese medical science is thought and is entered the lung Liver Channel by Folium Mori bitter but sweet flavor, cold, light clear the evacuation, and sweet cool moistening, but clearing away lung-heat, lung moistening is dry, to alleviate deficiency of both vital energy and Yin, production of dryness-heat in the interior, the main symptom of thirst and drinking; Compendium of Material Medica record Folium Mori have the improving eyesight long hair, only quench one's thirst, and essentials of Matea Medica record Folium Mori are only quenched one's thirst for tea.Select we to be based on for chief component the combination that modern study and traditional Chinese medical science ancient books medical science are put down in writing science on Folium Mori.Selecting Fructus Arctii to add this formula, is because Fructus Arctii has the excretion rate that reduces blood glucose, reduces urine protein, can be by alleviating height filtration, the HT of kidney, thus renal function protecting.Simultaneously, Fructus Arctii has stronger aldose reductase inhibitory action, can be used for the treatment of diabetic complication---as diabetic cataract, retinopathy, keratopathy and diabetic peripheral neuropathy etc.The traditional Chinese medical science is thought that Fructus Arctii is arduous and is trembled with fear, and to Qiu Naicheng, obtains the refrigerant gas in the world, has lung heat clearing and rushes down the stomach effect.Select Herba Centellae to add we, because Herba Centellae has the activity of Inhibiting α-glucosidase, there is obvious reduction blood sugar level, lose weight, reduce blood fat and insulin resistance index level, improve the effect of type 2 diabetes mellitus Insulin Resistance of Rats, simultaneously Asiatic polysaccharide have protein phosphatase PTP1B inhibitor effect, and regulate immune effect.The traditional Chinese medical science is thought, Herba Centellae, and bitter, acrid, cold, return the liver,spleen,kidney warp, has clearing away heat-damp and promoting diuresis, the effect of removing toxic substances and promoting subsidence of swelling.Select Semen Vitis viniferae to add this formula, because applicant's process test of many times, confirmed that the procyanidin in the Semen Vitis viniferae raises certain resistance inhibitor action is arranged blood fat, the scalable blood fat, reduce blood lipid level, reduce the content of liver cholesterol, triglyceride, and procyanidin also has the effect of auxiliary scavenger interior free yl.But due to the effect of procyanidin scavenger interior free yl, be equipped with again and there are the Folium Mori that can suppress harmful peroxide nucleus formation in body and combine use, can bring into play coordinative role, further strengthen the ability of directly or indirectly removing interior free yl, reach the effect that comprehensive system is removed harmful material in body; And Fructus Arctii, Herba Centellae, Folium Mori, procyanidin all can improve metabolism of blood glucose, reduce blood fat.Radix Panacis Quinquefolii and Folium Mori also can promote insulin secretion, so their Integrated usings can play to human body the effect of good auxiliary hyperglycemic.Therefore all product share, can mutually promote, mutual synergism, reach real hypoglycemic purpose.
So, one of the object of the invention is, principle based on modern pathology molecular mechanism and Traditional Chinese medical theory combination, through a large amount of research, find, the mixture of Radix Panacis Quinquefolii or extract, Folium Mori or extract, Herba Centellae or extract, Fructus Arctii or extract, Semen Vitis viniferae or extract has significant curative effect for the treatment of diabetes, can be used for being prepared into the medicine for the treatment of diabetes.This modern composition of natural products, wherein contained a large amount of Protein-tyrosine-phosphatases (PTP1B) inhibitor composition, aldose reductase suppresses composition, the alpha-glucosidase inhibitor composition, promote the insulin secretion composition, component for reducing blood fat, eliminate the oxygen-derived free radicals composition, mutual synergism, many target spots, the multipath effect, diabetes patient's body is fundamentally regulated in five medicine combinations comprehensively, improve diabetes patient's physical condition, and, the contained different effective substances of Chinese medicine of the five flavours have very clear and definite blood sugar lowering pharmacology effect from different action target spots and approach, can be by diabetes patient's blood glucose regulation to normal level.Can be used for medicine and health product that preparation has the relevant diseases such as the diabetes of preventing and treating and complication thereof.There is obvious novelty and technological progress.
Two of the object of the invention is, each Chinese medicine synergism in this prescription, reduced insulin resistant, improved the sensitivity of insulin, make it give play to original biological effect, thereby reach the therapeutical effect that reduces blood glucose and diabetic complication, the effect that this natural compositions reaches is that current existing chemical drugs and Chinese medicine preparation treatment diabetes are not available, and this is the most outstanding contribution of the present invention.
Technical problem to be solved by this invention is from natural plants Radix Panacis Quinquefolii, Folium Mori, Herba Centellae, Fructus Arctii, Semen Vitis viniferae to extract active component with blood sugar reducing function, prepares composition of natural products.
The invention provides the compositions that a kind of Chinese medicine with relevant diseases such as the diabetes of preventing and treating and complication thereof is made, said composition comprises Radix Panacis Quinquefolii 50-100 part, Folium Mori 200-500 part, Herba Centellae 100-300 part, Fructus Arctii 100-300 part, Semen Vitis viniferae 50-200 part.Can be also Radix Panacis Quinquefolii extract 10-30 part, Folium Mori extract 40-100 part, Herba Centellae extract 20-50 part, the 20-50 of Fructus Arctii extract part, Semen Vitis viniferae extract 10-30 part.According to aforementioned proportion mixing composition active ingredient and pharmaceutic adjuvant, make.
Another object of the present invention has been to provide extracts respectively the method for active component from Radix Panacis Quinquefolii, Folium Mori, Herba Centellae, Fructus Arctii, Semen Vitis viniferae, and the method comprises:
(1) Folium Mori extract preparation: 8-20 times of deionized water for Folium Mori, extract 1-3 time, each 1-3 hour, filter, and filtrate is concentrated, dry, pulverize, and obtains Folium Mori extract;
(2) Herba Centellae extract preparation: 8-20 times of deionized water for Herba Centellae, extract 2-4 time, each 1-3 hour, filter, and filtrate is concentrated, dry, pulverize, and obtains Herba Centellae extract;
(3) Fructus Arctii extract's preparation: the alcoholic solution of 8-14 times of 40%-90% for Fructus Arctii, extract 2-3 time, each 1-3 hour, filter, and filtrate recycling ethanol is concentrated, dry, pulverize, and obtains Fructus Arctii extract;
(4) Semen Vitis viniferae extract preparation: the alcoholic solution of 8-14 times of 30%-80% for Semen Vitis viniferae, extract 2-3 time, each 1-3 hour, filter, and filtrate recycling ethanol is concentrated, is drying to obtain Semen Vitis viniferae extract;
(5) Radix Panacis Quinquefolii powder is broken into fine powder.
Another object of the present invention has been to provide above-mentioned active component of separating from Radix Panacis Quinquefolii, Folium Mori, Herba Centellae, Fructus Arctii, Semen Vitis viniferae and has prevented and treated the medicine of diabetes and the application in health food in preparation.
The present invention with respect to prior art there is determined curative effect, have no side effect, taking convenience, cheap.
Because the present invention discloses the effect that the compositions be comprised of Radix Panacis Quinquefolii or extract, Folium Mori or extract, Herba Centellae or extract, Fructus Arctii or extract, Semen Vitis viniferae or extract has the relevant diseases such as the diabetes of preventing and treating and complication thereof first; therefore; by this compositions separately or coordinate and make medicament with other active constituent or adjuvant; so long as this medicament all belongs to protection scope of the present invention for prevention and treatment hyperglycemia and complication thereof.Compositions of the present invention, when making any dosage form, all has the effect of prevention and treatment hyperglycemia.
By Radix Panacis Quinquefolii or extract, the compositions (abbreviation compositions) that Folium Mori or extract, Herba Centellae or extract, Fructus Arctii or extract, Semen Vitis viniferae or extract form has hypoglycemic activity, by following pharmacodynamic experiment, is confirmed.
1, this product compositions causes the impact of mice hyperglycemia on glucose
Get 60 of male and female half and half mices, be divided at random 6 groups by body weight, be respectively blank group (10ml/kg water), model control group (10ml/kg water), jade plate Xiaoke Tablets group, compositions group are according to the following table administration, in 7 days every day gastric infusion once, the gavage volume is 10ml/kg, and before the last administration, fasting is 5 hours, and the last administration is after 2 hours, except the blank group, all the other respectively organize equal lumbar injection glucose 2g/kg, respectively at after injectable dextrose monohydrate 0.5,1 and 2 hour, by sacrifice of animal, get blood, with glucose oxidase method, survey blood glucose.Result of the test is in Table 1.
Table 1 this product compositions causes the impact of mice hyperglycemia on glucose
With model control group, compare: * P<0.05; * P<0.01; * * P<0.001
Result shows: this product can obviously reduce the hyperglycemia that glucose causes in 0.5 and 1 hour after injectable dextrose monohydrate, and obvious dose-effect relationship is arranged, and in the time of 2 hours, there is no obviously to reduce the mice hyperglycemia that glucose causes.
2, this product causes the impact of mice hyperglycemia on epinephrine
Get 60 of male and female half and half mices, be divided at random 6 groups by body weight, be respectively blank group (10ml/kg water), model control group (10ml/kg water), jade plate Xiaoke Tablets group, compositions group are according to the following table administration, in 7 days every day gastric infusion once, the gavage volume is 10ml/kg, and before the last administration, fasting is 5 hours, and the last administration is after 2 hours, except the blank group, all the other respectively organize equal lumbar injection epinephrine 240ug/kg, respectively at after Injection of Adrenaline 0.5,1 and 2 hour, by sacrifice of animal, get blood, with glucose oxidase method, survey blood glucose.Result of the test is in Table 2.
Table 2 this product compositions causes the impact of mice hyperglycemia on epinephrine
With model control group, compare: * P<0.05; * P<0.01; * * P<0.01
Result shows: this product compositions all can obviously reduce the hyperglycemia that epinephrine causes in observed time range, especially remarkable with effect in 0.5,1 hour.Within 2 hours, effect is relatively poor, but certain effect is also arranged.
3, this product compositions causes the impact of mice hyperglycemia on streptozotocin
80 of male mices, get 10 at random as the blank group, and all the other mouse tail vein injection streptozotocin (with 0.05M citric acid pH4.5 solution preparation, using immediately in 4 ℃ of ice baths) 200mg/kg, cause diabetes model.Inject latter 72 hours mice socket of the eye venous blood samplings and survey blood glucose, deletion does not cause the diabetes model, and the person (surveys front fasting 12 hours, blood glucose value is lower than 11.11mmol/L), continue to employ mice and be divided at random 5 groups, 10 every group, be administered once every day by dosage shown in table 3 in 7 days, after the last administration 2 hours,, the socket of the eye venous blood sampling, survey blood glucose with ortho-aminotoluene method (ultramicro method).Result of the test is in Table 3.
Table 3 this product compositions causes the impact of mice hyperglycemia on streptozotocin
With model control group, compare: * P<0.05; * P<0.01; * * P<0.01
Result shows: the high, medium and low dosage group of this product compositions causes that to streptozotocin the mice hyperglycemia all has obvious reducing effect.
4, the impact of this product compositions on alloxan diabetes mouse blood sugar and serum insulin levels
80 of male mices, get at random 10 as the blank group, all the other mouse tail vein injection alloxan 70mg/kg, cause diabetes model, inject latter 96 hours mice socket of the eye venous blood samplings and survey blood glucose with ortho-aminotoluene method (ultramicro method), delete do not cause diabetes model person or blood glucose superelevation person (blood glucose value discards lower than 20mmol/L with higher than 40mmol/L), continue to employ mice and be divided at random immediately 5 groups, every group 10, weigh every day, amount of drinking water, appetite and urine is amount just, in 12 days, by dosage shown in table 4, be administered once every day, after the last administration 2 hours, the socket of the eye venous blood sampling, separation of serum, survey blood glucose with glucose oxidase method, measure insulin content with radio immunoassay.Result of the test is in Table 4.
The impact of table 4 this product on alloxan diabetes mouse blood sugar and serum insulin levels
With model control group, compare: * P<0.05; * P<0.01
Result shows: under dosage used, this product causes that to alloxan the mice hyperglycemia has obvious reducing effect, and obvious dose-effect relationship is arranged, and can obviously improve the symptoms more than three such as alloxan hyperglycemia mice polydipsia, polyphagia, polyuria, but weight of mice is had no significant effect; Its each dosage group also has facilitation to the release of insulin in alloxan hyperglycemia mice serum.
The present invention is described in detail by the following examples, but does not mean that the present invention only limits to this, and specific embodiments is as follows:
embodiment 1the preparation of extract
(1) Folium Mori extract preparation: 14 times of distilled water for Folium Mori, extract 2 times, each 2 hours, to filter, filtrate is concentrated, is drying to obtain Folium Mori extract;
(2) Herba Centellae extract preparation: 14 times of distilled water for Herba Centellae, extract 3 times, each 1 hour, to filter, filtrate is concentrated, is drying to obtain Herba Centellae extract;
(3) Fructus Arctii extract preparation: the alcoholic solution of 8 times 70% for Fructus Arctii, extract 3 times, each 2 hours, filter, filtrate recycling ethanol, concentrate, and is drying to obtain Fructus Arctii extract;
(4) Semen Vitis viniferae extract preparation: the alcoholic solution of 8 times 50% for Semen Vitis viniferae, extract 3 times, each 1 hour, filter, filtrate recycling ethanol, concentrate, and is drying to obtain Semen Vitis viniferae extract;
embodiment 2(capsule)
Radix Panacis Quinquefolii fine powder 50g, Folium Mori extract 180g, Herba Centellae extract 70g, the 70g of Fructus Arctii extract, Semen Vitis viniferae extract 50g, right amount of auxiliary materials, mix homogeneously, granulate, drying, granulate, incapsulate, and makes 1000, obtains.Each 2, every day 2 times.
embodiment 3, (tablet)
Radix Panacis Quinquefolii fine powder 50g, Folium Mori extract 180g, Herba Centellae extract 70g, the 70g of Fructus Arctii extract, Semen Vitis viniferae extract 50g, right amount of auxiliary materials, mix homogeneously, granulate, drying, granulate, tabletting, make 1000, obtains.Each 2, every day 2 times.
Claims (3)
1. the Chinese medicine composition with relevant diseases such as the diabetes of preventing and treating and complication thereof, is characterized in that, it is to be made by the raw material of following weight parts:
Radix Panacis Quinquefolii 50-100 part, Folium Mori 200-500 part, Herba Centellae 100-300 part, Fructus Arctii 100-300 part, Semen Vitis viniferae 50-200 part.
2. the Chinese medicine composition with relevant diseases such as the diabetes of preventing and treating and complication thereof according to claim 1, is characterized in that, it is to be made by the raw material of following weight parts:
Radix Panacis Quinquefolii extract 10-30 part, Folium Mori extract 40-100 part, Herba Centellae extract 20-50 part, the 20-50 of Fructus Arctii extract part, Semen Vitis viniferae extract 10-30 part.
3. Chinese medicine composition according to claim 1, it is characterized in that: the preparation method of described Chinese medicine composition comprises the following steps:
(1) 8-20 times of deionized water for Folium Mori, extract 1-3 time, and each 1-3 hour, filter, and filtrate is concentrated, dry, pulverize, and obtains Folium Mori extract;
(2) 8-20 times of deionized water for Herba Centellae, extract 2-4 time, and each 1-3 hour, filter, and filtrate is concentrated, dry, pulverize, and obtains Herba Centellae extract;
(3) alcoholic solution of 8-14 times of 40%-90% for Fructus Arctii, extract 2-3 time, and each 1-3 hour, filter, and filtrate recycling ethanol is concentrated, dry, pulverize, and obtains Fructus Arctii extract;
(4) alcoholic solution of 8-14 times of 30%-80% for Semen Vitis viniferae, extract 2-3 time, and each 1-3 hour, filter, and filtrate recycling ethanol is concentrated, dry, pulverize, and obtains Semen Vitis viniferae extract;
(5) Radix Panacis Quinquefolii powder is broken into fine powder;
(6) after 20 parts of Folium Mori extract 40-100 part of making, Herba Centellae extract 20-50 part, the 20-50 of Fructus Arctii extract part, Semen Vitis viniferae extract 10-30 part and Radix Panacis Quinquefolii powder are mixed by formula proportion, be mixed together with pharmaceutic adjuvant again, make according to a conventional method oral formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210146660.1A CN102631482B (en) | 2012-05-12 | 2012-05-12 | Chinese medicinal composition for preventing and treating diabetes and complications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210146660.1A CN102631482B (en) | 2012-05-12 | 2012-05-12 | Chinese medicinal composition for preventing and treating diabetes and complications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102631482A CN102631482A (en) | 2012-08-15 |
| CN102631482B true CN102631482B (en) | 2014-01-08 |
Family
ID=46616162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210146660.1A Active CN102631482B (en) | 2012-05-12 | 2012-05-12 | Chinese medicinal composition for preventing and treating diabetes and complications |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102631482B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104208478A (en) * | 2014-09-12 | 2014-12-17 | 灌阳千家洞瑶之源生物科技有限公司 | Yao medicine composition for treating diabetes mellitus and preparation method thereof |
| CN108095118A (en) * | 2018-01-17 | 2018-06-01 | 长江师范学院 | A kind of slimming health food |
| CN112980772A (en) * | 2021-03-09 | 2021-06-18 | 广东医科大学 | Method for detecting autophagy effect of anthocyanin-induced mouse islet beta cells |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1401365A (en) * | 2002-09-19 | 2003-03-12 | 太极集团有限公司 | Chinese health medicine |
| CN1586596A (en) * | 2004-07-26 | 2005-03-02 | 北京科信必成医药科技发展有限公司 | American ginseng and its extract oral disintegration tablet and its preparing process |
| CN101757115A (en) * | 2008-10-10 | 2010-06-30 | 郇心清 | American ginseng mulberry leaf buccal tablet |
-
2012
- 2012-05-12 CN CN201210146660.1A patent/CN102631482B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1401365A (en) * | 2002-09-19 | 2003-03-12 | 太极集团有限公司 | Chinese health medicine |
| CN1586596A (en) * | 2004-07-26 | 2005-03-02 | 北京科信必成医药科技发展有限公司 | American ginseng and its extract oral disintegration tablet and its preparing process |
| CN101757115A (en) * | 2008-10-10 | 2010-06-30 | 郇心清 | American ginseng mulberry leaf buccal tablet |
Non-Patent Citations (6)
| Title |
|---|
| 刘湘红等.葡萄籽原花青素对2型糖尿病大鼠血清中SOD GSH MDA及NO表达的影响.《中国药物与临床》.2008,第8卷(第03期),193-195. * |
| 李向荣等.桑叶提取液对实验性糖尿病大鼠血糖、LPO含量及SOD水平的影响.《中国老年学杂志》.2003,第23卷(第02期),101-103. |
| 桑叶提取液对实验性糖尿病大鼠血糖、LPO含量及SOD水平的影响;李向荣等;《中国老年学杂志》;20030220;第23卷(第02期);101-103 * |
| 王海颖等.牛蒡子提取物对糖尿病大鼠肾脏蛋白激酶C活性作用的研究.《中国中医基础医学杂志》.2002,第8卷(第05期),62-63. * |
| 积雪草对2型糖尿病大鼠胰岛素抵抗影响的研究;郑承红等;《内科急危重症杂志》;20111231;第17卷(第02期);88-90 * |
| 郑承红等.积雪草对2型糖尿病大鼠胰岛素抵抗影响的研究.《内科急危重症杂志》.2011,第17卷(第02期),88-90. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102631482A (en) | 2012-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041118B (en) | Composition with effects of reducing blood sugar and reducing blood lipid | |
| CN102727586A (en) | Composition for preventing and treating diabetes | |
| CN101543248B (en) | A cold tea especially suitable for 'three high and one acid' population and method for preparing same | |
| CN101085039B (en) | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method | |
| CN103349121B (en) | Hyperglycemia-hyperlipidemia-hypertension relieving health protection tea and preparation method thereof | |
| CN104173451A (en) | Application of natural pharmaceutical composition in blood glucose-reducing drugs and health food | |
| CN102631482B (en) | Chinese medicinal composition for preventing and treating diabetes and complications | |
| CN104474472B (en) | Buccal lozenge of lectuce tea and its production method with three high drop effect | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN102579587B (en) | Traditional Chinese medicine composition for preventing and treating diabetes and complications thereof | |
| CN101601814A (en) | A kind of Chinese medicinal capsule for the treatment of diabetes | |
| CN1332688C (en) | Medication for treating dementia in blood vessel type, and preparation method | |
| CN112402569A (en) | Anti-fatigue health product and preparation method thereof | |
| CN104815140A (en) | Composition for preventing or/and treating diabetes and preparation method of composition | |
| CN102579589B (en) | Application of Chinese medicinal composition in preparing hypoglycemic drugs or health-promoting products | |
| KR101600745B1 (en) | A pharmaceutical composition comprising the complex extract of herb medicine | |
| CN103830495A (en) | Traditional Chinese medicine composition for treating fundus hemorrhage caused by diabetic retinopathy and preparation method thereof | |
| CN103525640A (en) | Energy-keeping yang-tonifying wine | |
| CN1463734A (en) | A prepared Chinese medicine for treating diabetes mellitus and method for preparing same | |
| CN1267143C (en) | Method for preparing compound medicinal capsule and powder for nourishing yin | |
| CN102824446B (en) | Medicinal composition with anti-fatigue effect as well as preparation method and application thereof | |
| KR20050102017A (en) | Composition using vinegar processed ginseng preparation for treatment and prevention of type Ⅱ diabetes and metabolic syndrome | |
| CN102366481B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN105169187A (en) | Composition and application and preparation method thereof and medicines and food containing composition | |
| CN104799391A (en) | Oolong tea polysaccharide compound type weight-losing solid beverage and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Shanheng Inventor before: Nan Minlun Inventor before: He Yufang Inventor before: Wang Lianping Inventor before: Zhao Yuwei Inventor before: Ma Jisheng Inventor before: Zhao Quancheng |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170531 Address after: 264006 No. 14, Xiangjiang Road, Yantai Development Zone, Shandong 1, China Patentee after: YANTAI HUAXIN BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: 130012 Changchun high tech Zone, Jilin pioneering Street No. 155 Patentee before: Zhao Quancheng |
|
| CB03 | Change of inventor or designer information |
Inventor after: Han Chaowu Inventor after: Hou Jian Inventor before: Wang Shanheng |
|
| CB03 | Change of inventor or designer information |